clinical trial · NCT05866627
A Study to Assess the Effect of Famotidine on the Drug Levels of Afimetoran in Healthy Participants
Bristol-Myers Squibb·phase1·completed·n = 32
Healthy VolunteersFamotidineAfimetoran
brief summary
The purpose of this study is to confirm there is no significant effect of gastric pH changes of famotidine on the drug levels of afimetoran in healthy participants.
started
Jul 4, 2023
primary completion
Sep 29, 2023
completion
Sep 29, 2023
last updated
May 13, 2026
official title
A Phase 1 Open-label, 2-Part Crossover Study to Assess the Effect of Acid-reducing Agent Famotidine on the Pharmacokinetics of Afimetoran (BMS-986256) in Healthy Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol